How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,169 results for

Life-Threatening Drug-Induced Rashes

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)

Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug) Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01299220 Recruitment Status : Withdrawn (Unable to enroll subjects by sponsor deadline) First Posted : February 18, 2011 Last Update Posted : January 16, 2013 Sponsor

2011 Clinical Trials

42. Increased type 2 innate lymphoid cells in patients with drug reaction with eosinophilia and systemic symptom. (PubMed)

Increased type 2 innate lymphoid cells in patients with drug reaction with eosinophilia and systemic symptom. Drug reaction with eosinophilia and systemic symptom (DRESS) is life-threatening disorder with an estimated mortality of 2%. Recently, type II innate lymphoid cells (ILC2s) has been implicated as an important contributor to the pathogenesis of allergic disorders. However, whether the roles of ILC2s and ILC2-associated cytokines in DRESS remain unclear. Herein, we enrolled 54 (...) participants (including 24 DRESS patients and 30 healthy controls), and identified the increased ST2+ILC2s population in skin lesions/blood. In addition, serum sST2, IL-5, and TSLP levels were significantly elevated at the acute stage of DRESS patients. Decreased ILC2s population, serum sST2, and IL-5, accompanied with rash, eosinophilia and alanine aminotransferase (ALT) improvement was observed after steroid treatment. In the delayed-responders group (n=13), serum IL-33, sST2, IL-5, and TSLP levels were

2019 Journal of Investigative Dermatology

43. Contrast-induced Nephropathy

Contrast-induced Nephropathy Comparative Effectiveness of Preventive Measures Comparative Effectiveness Review Number 156 Contrast-Induced Nephropathy: Comparative Effectiveness Review Number 156 Contrast-Induced Nephropathy: Comparative Effectiveness of Preventive Measures Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2012-00007-I Prepared by: Johns Hopkins University (...) surveillance report describing the methodology and findings will be found on the Effective Health Care Program Web site at www.effectivehealthcare.ahrq.gov. Search on the title of the report. Persons using assistive technology may not be able to fully access information in this report. For assistance, contact EffectiveHealthCare@ahrq.hhs.gov. Suggested citation: Subramaniam RM, Wilson RF, Turban S, Suarez-Cuervo C, Zhang A, Sherrod C, Aboagye J, Eng J, Choi MJ, Hutfless S, Bass EB. Contrast-Induced

2016 Effective Health Care Program (AHRQ)

44. Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). (PubMed)

Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). Previous studies suggest tetracycline and other antibiotics lessen the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash. This study sought to confirm such findings.Patients starting an EGFR inhibitor were eligible for this randomized, double-blinded, placebo-controlled (...) study and had to be rash-free. They were then randomly assigned to tetracycline 500 mg orally twice a day for 28 days versus a placebo. Rash development and severity (monthly physician assessment and weekly patient-reported questionnaires), quality of life (SKINDEX-16), and adverse events were monitored during the 4-week intervention and then for an additional 4 weeks. The primary objective was to compare the incidence of grade 2 or worse rash between study arms; 32 patients per group provided a 90

Full Text available with Trip Pro

2011 Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

45. Adverse drug reactions

of the reaction. This will determine whether urgent action is required or whether the person can be in primary care. For example, a cough due to an angiotensin-converting enzyme inhibitor can be troublesome but not life threatening, but an anaphylactic reaction is a medical emergency. The nature of the presenting condition may strongly suggest that it is an adverse drug reaction (ADR). For example, the following conditions are often ADRs: Acute dystonias Blood dyscrasias Skin reactions, such as Stevens (...) [ ] and on what CKS considers to be good clinical practice. Managing a suspected reaction How should I manage a person with a suspected adverse drug reaction? Following an : Arrange emergency hospital admission if the adverse drug reaction (ADR) is serious or life threatening. Assess whether the ADR can be managed in primary care. Consider seeking specialist advice. If the ADR can be managed in primary care: Review and discuss treatment options with the person. These may include: Stopping the suspected drug

2017 NICE Clinical Knowledge Summaries

46. Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome Induced by Levetiracetam in a Pediatric Patient. (PubMed)

Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome Induced by Levetiracetam in a Pediatric Patient. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare, life-threatening hypersensitivity drug reaction. Patients present with cutaneous rash, fever, lymphadenopathy, hematologic abnormalities with eosinophilia and atypical lymphocytes, and visceral organ involvement. The prognosis of DRESS syndrome is related to the degree of end-organ damage (...) , and the mortality rate is approximately 10%.We report a 9-year-old girl treated with only levetiracetam because of intracranial space occupying mass-related seizures. The patient developed pharyngitis accompanied by exudative membrane, bilateral cervical lymphadenopathy, tender hepatomegaly, skin rash, and fever after 19 days of levetiracetam therapy. Laboratory findings revealed leukocytosis, lymphocytosis with an atypical lymphocytosis, eosinophilia, thrombocytopenia, and elevated serum transaminases

2015 Journal of Emergency Medicine

47. Pediatrics, Diaper Rash (Treatment)

Pediatrics, Diaper Rash (Treatment) Diaper Rash Treatment & Management: Emergency Department Care, Consultations Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvODAxMjIyLXRyZWF0bWVudA== processing > Diaper Rash (...) Treatment & Management Updated: Nov 09, 2018 Author: Rania Dib, MD; Chief Editor: Kirsten A Bechtel, MD Share Email Print Feedback Close Sections Sections Diaper Rash Treatment Emergency Department Care The emergency physician's role in this disease is to make a proper diagnosis, to educate the caregivers, and to treat any acute complications that have occurred due to an untreated rash. Irritant contact dermatitis, miliaria, and intertrigo often can be treated nonmedically through changes in diapering

2014 eMedicine Emergency Medicine

48. Pediatrics, Diaper Rash (Diagnosis)

. Granuloma gluteale infantum Granuloma gluteale infantum is a rare disorder. [ ] It is not very well understood, but it probably represents an unusual inflammatory response to long-standing irritation, candidiasis, or fluorinated corticosteroids. Previous Next: Epidemiology Frequency United States Diaper rash is the most common dermatitis found in infancy. Prevalence has been variably reported from 4-35% in the first 2 years of life. Incidence triples in babies with diarrhea. It is not unusual for every (...) of 19.4% in those aged 3-6 months. [ ] One large British study reported diaper dermatitis in 25% of children aged 1 month. A Nigerian study conducted in 1995-1996 identified diaper dermatitis in 7% of children. A study in Kuwait noted that diaper dermatitis occurs in 4% of pediatric dermatology cases. These studies do not distinguish between common or generic diaper dermatitis and secondary diaper dermatitis. Mortality/Morbidity See the list below: This disease is not usually life threatening; however

2014 eMedicine Emergency Medicine

49. Pediatrics, Diaper Rash (Overview)

. Granuloma gluteale infantum Granuloma gluteale infantum is a rare disorder. [ ] It is not very well understood, but it probably represents an unusual inflammatory response to long-standing irritation, candidiasis, or fluorinated corticosteroids. Previous Next: Epidemiology Frequency United States Diaper rash is the most common dermatitis found in infancy. Prevalence has been variably reported from 4-35% in the first 2 years of life. Incidence triples in babies with diarrhea. It is not unusual for every (...) of 19.4% in those aged 3-6 months. [ ] One large British study reported diaper dermatitis in 25% of children aged 1 month. A Nigerian study conducted in 1995-1996 identified diaper dermatitis in 7% of children. A study in Kuwait noted that diaper dermatitis occurs in 4% of pediatric dermatology cases. These studies do not distinguish between common or generic diaper dermatitis and secondary diaper dermatitis. Mortality/Morbidity See the list below: This disease is not usually life threatening; however

2014 eMedicine Emergency Medicine

50. Pediatrics, Diaper Rash (Follow-up)

dermatitis resolve by the third year of life. Granuloma gluteale infantum tends to resolve spontaneously over the course of a few months. Langerhans cell histiocytosis is usually a fatal disease. Previous Next: Patient Education See the list below: The parents of the patient should be educated about proper diaper hygiene and the need for frequent diaper changes to prevent future episodes. Parents should be taught how to recognize changes in the rash indicative of a secondary infection and should (...) Pediatrics, Diaper Rash (Follow-up) Diaper Rash Follow-up: Further Outpatient Care, Further Inpatient Care, Deterrence/Prevention Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvODAxMjIyLWZvbGxvd3Vw processing

2014 eMedicine Emergency Medicine

51. Portable Oxygen Concentrator Improvements to Physical Activity, Oxygen Usage, and Quality of Life in Chronic Obstructive Pulmonary Disease Patients Using Long-term Oxygen Therapy (POC-STEP)

, and/or acute bronchitis requiring antibiotics, or new/increased dose of systemic corticosteroids. Patient has had thoracic surgery or another procedure in the six months prior to enrollment that is likely to cause instability of pulmonary status. Patient has an open skin ulcer or rash where the activity monitor will be worn on the body. Patient has a life expectancy < 1 year. Patient has non-COPD lung disease that may affect oxygenation or survival. Patient has a planned intervention(s) requiring (...) Portable Oxygen Concentrator Improvements to Physical Activity, Oxygen Usage, and Quality of Life in Chronic Obstructive Pulmonary Disease Patients Using Long-term Oxygen Therapy (POC-STEP) Portable Oxygen Concentrator Improvements to Physical Activity, Oxygen Usage, and Quality of Life in Chronic Obstructive Pulmonary Disease Patients Using Long-term Oxygen Therapy (POC-STEP) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting

2018 Clinical Trials

52. Pulling the Plug on the First Gene Therapy Drug

Pulling the Plug on the First Gene Therapy Drug Pulling the Plug on the First Gene Therapy Drug | PLOS Blogs Network PLOS Blogs Staff Blogs Blogs by Topic Biology & Life Sciences Earth & Environmental Sciences Multi-disciplinary Sciences Medicine & Health Research Analysis & Scientific Policy Diverse perspectives on science and medicine Staff Blogs Blogs by Topic Biology & Life Sciences Earth & Environmental Sciences Multi-disciplinary Sciences Medicine & Health Research Analysis & Scientific (...) is it with changing disease names???). It causes extremely high blood triglyceride levels and, in some patients, recurrent excruciating abdominal pain. Rash and enlarged liver and spleen are also part of the picture. Some of the worst cases are in children and teens. Existing triglyceride-lowering drugs are ineffective because the cause differs. So the only approach, nearly impossible to do, is to eat as little fat as possible. The gene therapy is delivered in 42 injections into leg muscles, once, with a viral

2017 PLOS Blogs Network

53. March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection

March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection MARCH 2014 SUPPLEMENT TO THE 2013 CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION RECOMMENDATIONS FOR A PUBLIC HEALTH APPROACH SUPPLEMENTSUPPLEMENT MARCH 2014 SUPPLEMENT TO THE 2013 CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION RECOMMENDATIONS FOR A PUBLIC (...) HEALTH APPROACH4 WHO Library Cataloguing-in-Publication Data MARCH 2014 SUPPLEMENT TO THE 2013 CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION. Recommendations for a public health approach. I.World Health Organization. ISBN 978 92 4 150683 0 Subject headings are available from WHO institutional repository © World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www

2014 World Health Organisation HIV Guidelines

54. A Rare Case of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Glimepiride, the Unlikely Culprit (PubMed)

A Rare Case of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Glimepiride, the Unlikely Culprit Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare and challenging entity which can be life threatening and is associated with many medications. Yet, Glimepiride has never been reported as offending agent. We present here the first case of Glimepiride induced DRESS syndrome. A 40-year-old male with type 2 diabetes mellitus was prescribed Glimepiride. One (...) month later, the patient presented with diffuse rash, fever, swelling of extremities and jaundice. The leucocyte count at presentation was 22,000 cells/microL and absolute eosinophil count 5,400 cells/microL, with no atypical cells on peripheral blood smear. Skin biopsy was non-specific. Other sources of infections such as parasitic infections, HIV, viral hepatitis were ruled out. Patient improved symptomatically on discontinuation of Glimepiride and improved dramatically on steroids. DRESS syndrome

Full Text available with Trip Pro

2018 Mædica

55. Safety and Therapeutic Drug Monitoring of Cefazolin in Continuous Renal Replacement Therapy

hypersensitivity or allergic reaction to cefazolin (a history of mild rash followed by uneventful re-exposure and/or red man syndrome is not a contraindication) Any rapidly-progressing disease or immediately life-threatening illness (defined as imminent death within 48 hours in the opinion of the investigator) Any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the patient or the quality of study data Females that are pregnant or breastfeeding Contacts (...) Safety and Therapeutic Drug Monitoring of Cefazolin in Continuous Renal Replacement Therapy Safety and Therapeutic Drug Monitoring of Cefazolin in Continuous Renal Replacement Therapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2018 Clinical Trials

56. Myocarditis Associated with Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Case Report and Review of the Literature (PubMed)

Myocarditis Associated with Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Case Report and Review of the Literature BACKGROUND Drug reaction with eosinophilia and systemic symptoms (DRESS) is a clinical syndrome that can be life-threatening, depending on the organs involved. Although DRESS commonly presents with skin lesions, myocarditis and pericarditis associated with DRESS, although rare, can be fatal. A case of DRESS associated with myocarditis is presented (...) with a review of the literature of 43 reported cases of DRESS associated with myocarditis that included the present case, to evaluate the effectiveness of treatment of DRESS with corticosteroids. CASE REPORT A 33-year-old man presented with fever, diarrhea, and a diffuse maculopapular rash, four weeks after being treated with antibiotics and a nonsteroidal anti-inflammatory drug (NSAID). He developed renal failure, liver dysfunction, and profound hypotension with severe left ventricular dysfunction

Full Text available with Trip Pro

2018 The American journal of case reports

57. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Secondary to Furosemide: Case Report and Review of Literature (PubMed)

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Secondary to Furosemide: Case Report and Review of Literature BACKGROUND DRESS is a rare, life threatening syndrome that occurs following exposure to certain medications, most commonly antibiotics and antiepileptics. While sulfonamide antibiotics are frequently implicated as causative agents for DRESS syndrome, furosemide, a nonantibiotic sulfonamide, has not been routinely reported as the causative agent despite its (...) and thrombocytopenia. He was treated empirically for atypical pneumonia, and after resuming furosemide for fluid excess, he developed AKI, worsening rash, fever and eosinophilia of 2,394 cell/µL. Extensive infectious and inflammatory work up was negative. Skin biopsy was consistent with a severe drug reaction. Latency from introduction and clinical worsening following re-exposure indicated furosemide was the likely inciter of DRESS. The RegiSCAR scoring system categorized this case as "definite" with a score of 8

Full Text available with Trip Pro

2018 The American journal of case reports

58. Sloughing skin in intravenous drug user (PubMed)

for toxic shock syndrome toxin antibody was positive. She was treated with antibiotics and intravenous gamma globulin (IVIG). Due to her worsening rash she was transferred to a burns unit. She was diagnosed with Purpura fulminans (PF) which is a skin manifestation of DIC and has a rare association with Staphylococcus aureus infection.The main focus of this case report is to emphasise this rare association, prompt an early diagnosis and referral to prevent life threatening complications. (...) Sloughing skin in intravenous drug user A 32 year old female, an active intravenous drug user, was admitted for fever, myalgias and an erythematous macular rash on her distal extremities. She quickly decompensated and developed septic shock. Her examination was significant for a progressive rash which within two days developed bullae and necrosis with progression to a confluent rash involving her palms and soles (Figs. 1 and 2). Her rash involved nearly one third of her body with what

Full Text available with Trip Pro

2018 IDCases

59. XLIMus Drug Eluting Stent: a randomIzed Controlled Trial to Assess Endothelization

coagulopathy (including heparin-induced thrombocytopenia), or will refuse blood transfusions; Previous coronary intervention on target vessel in the 3-months prior to enrollment; Non-cardiac co-morbid conditions with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment); Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period; Previously documented left (...) XLIMus Drug Eluting Stent: a randomIzed Controlled Trial to Assess Endothelization XLIMus Drug Eluting Stent: a randomIzed Controlled Trial to Assess Endothelization - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2018 Clinical Trials

60. Drug-reaction eosinophilia and systemic symptoms and drug-induced hypersensitivity syndrome. (PubMed)

Drug-reaction eosinophilia and systemic symptoms and drug-induced hypersensitivity syndrome. Drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug-induced hypersensitivity syndrome (DIHS), is a rare, severe cutaneous adverse reaction characterised by fever, rash, lymphadenopathy, eosinophilia and/or other leukocyte abnormalities, and internal organ involvement and often has a relapsing-remitting course despite withdrawal of the drug. The drugs that are most (...) *5701 has enabled pharmacogenetics screening to be employed successfully to minimise the occurrence of hypersensitivity. A prolonged course of oral corticosteroids is required to treat DRESS/DIHS, given the relapsing-remitting nature of the condition with i.v. immunoglobulin and valgangciclovir reserved for refractory or life-threatening cases. © 2013 The Australasian College of Dermatologists.

2013 Australasian Journal of Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>